AR096713A1 - Proceso de purificación para anticuerpos monoclonales - Google Patents

Proceso de purificación para anticuerpos monoclonales

Info

Publication number
AR096713A1
AR096713A1 ARP140102380A ARP140102380A AR096713A1 AR 096713 A1 AR096713 A1 AR 096713A1 AR P140102380 A ARP140102380 A AR P140102380A AR P140102380 A ARP140102380 A AR P140102380A AR 096713 A1 AR096713 A1 AR 096713A1
Authority
AR
Argentina
Prior art keywords
monoclonal antibodies
purification process
provides
monoclonal antibody
purification
Prior art date
Application number
ARP140102380A
Other languages
English (en)
Spanish (es)
Inventor
Bandyopadhyay Sanjay
Kumar Singh Avanish
Kumar Mendiratta Sanjay
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51655799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR096713(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of AR096713A1 publication Critical patent/AR096713A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
ARP140102380A 2013-06-25 2014-06-24 Proceso de purificación para anticuerpos monoclonales AR096713A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2145MU2013 IN2013MU02145A (cg-RX-API-DMAC7.html) 2013-06-25 2014-06-25

Publications (1)

Publication Number Publication Date
AR096713A1 true AR096713A1 (es) 2016-01-27

Family

ID=51655799

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102380A AR096713A1 (es) 2013-06-25 2014-06-24 Proceso de purificación para anticuerpos monoclonales

Country Status (19)

Country Link
US (1) US9708365B2 (cg-RX-API-DMAC7.html)
EP (1) EP3013849B1 (cg-RX-API-DMAC7.html)
JP (1) JP6039828B2 (cg-RX-API-DMAC7.html)
KR (1) KR101683415B1 (cg-RX-API-DMAC7.html)
CN (1) CN105263947A (cg-RX-API-DMAC7.html)
AR (1) AR096713A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014300486B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015031196A2 (cg-RX-API-DMAC7.html)
CA (1) CA2911874A1 (cg-RX-API-DMAC7.html)
EA (1) EA201592192A1 (cg-RX-API-DMAC7.html)
HK (1) HK1217344A1 (cg-RX-API-DMAC7.html)
IL (1) IL242649A (cg-RX-API-DMAC7.html)
IN (1) IN2013MU02145A (cg-RX-API-DMAC7.html)
MX (1) MX350610B (cg-RX-API-DMAC7.html)
NZ (1) NZ714079A (cg-RX-API-DMAC7.html)
SG (1) SG11201509502XA (cg-RX-API-DMAC7.html)
TW (1) TWI596107B (cg-RX-API-DMAC7.html)
WO (1) WO2014207763A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201508258B (cg-RX-API-DMAC7.html)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH088818Y2 (ja) 1989-12-21 1996-03-13 株式会社イナックス タイル用捺印装置
TWI398554B (zh) * 2010-07-29 2013-06-11 Zhen Ding Technology Co Ltd 電鍍裝置
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
MX374124B (es) 2013-10-16 2025-03-05 Outlook Therapeutics Inc Formulaciones de tampón para la estabilidad de anticuerpo mejorada.
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
EP3247718B1 (en) * 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
SG10201908027QA (en) * 2015-03-13 2019-10-30 Bristol Myers Squibb Co Use of alkaline washes during chromatography to remove impurities
WO2017032610A1 (en) * 2015-08-21 2017-03-02 F. Hoffmann-La Roche Ag Affinity chromatography purification with low conductivity wash buffer
KR20240121902A (ko) * 2015-08-21 2024-08-09 에프. 호프만-라 로슈 아게 친화성 크로마토그래피에서의 숙주 세포 단백질 감소 방법
HK1251583A1 (zh) 2015-08-21 2019-02-01 F. Hoffmann-La Roche Ag 在亲和层析中减少宿主细胞蛋白的方法
WO2017136433A1 (en) 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
WO2018034885A1 (en) 2016-08-16 2018-02-22 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
MX2019004316A (es) 2016-10-25 2019-08-05 Regeneron Pharma Metodos y sistemas para analisis de datos cromatograficos.
CA3039667A1 (en) 2016-10-28 2018-05-03 Merck Sharp & Dohme Corp. Purification process for removal of tyrosine sulfation antibody variants; purified compositions
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018116198A1 (en) 2016-12-23 2018-06-28 Serum Institute Of India Private Limited Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
TWI679052B (zh) * 2017-05-16 2019-12-11 南韓商Ｃｊ醫藥健康股份有限公司 使用親和力層析術純化抗體或其抗體片段的方法
EP3431168A1 (en) * 2017-07-19 2019-01-23 Bayer Aktiengesellschaft Élimination de médicament non lié après couplage conjugué anticorps-médicament
CN111201042B (zh) 2017-09-19 2024-05-10 里珍纳龙药品有限公司 减少粒子形成的方法以及由其形成的组合物
CN108101987A (zh) * 2017-11-17 2018-06-01 安徽未名生物医药有限公司 一种重组抗TNF-α全人源单克隆抗体的纯化方法
CN110128538B (zh) * 2018-02-09 2022-08-26 鲁南制药集团股份有限公司 一种纯化抗cd20人鼠嵌合单克隆抗体的方法
CN119881293A (zh) 2018-03-21 2025-04-25 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
US11407838B2 (en) * 2018-04-02 2022-08-09 Amgen Inc. Erenumab compositions and uses thereof
TW202448568A (zh) 2018-07-02 2024-12-16 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
EP3823594B1 (en) 2018-07-19 2025-02-05 Ichnos Sciences S.A. Liquid antibody formulation
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN111072773A (zh) * 2018-10-19 2020-04-28 菲鹏生物股份有限公司 抗体的纯化方法、抗体和应用
EP3643322A1 (en) * 2018-10-26 2020-04-29 Mabion SA Low aggregate anti cd20 ligand formulation
WO2020084503A1 (en) 2018-10-26 2020-04-30 Cadila Healthcare Limited A composition comprising antibody with reduced level of basic variants thereof
CN109320611B (zh) * 2018-10-31 2022-06-03 鼎康(武汉)生物医药有限公司 一种人鼠嵌合单克隆抗体生物类似药的纯化方法
CN111153993B (zh) * 2018-11-07 2024-06-28 正大天晴药业集团南京顺欣制药有限公司 抗TNF-α单克隆抗体的制备方法
CN109336969B (zh) * 2018-11-09 2021-02-12 杭州奕安济世生物药业有限公司 一种抗体的纯化方法
CN111269316B (zh) * 2018-12-04 2024-06-28 正大天晴药业集团南京顺欣制药有限公司 抗her2单克隆抗体的纯化方法
EP3916001A4 (en) * 2019-01-23 2022-10-19 Daiichi Sankyo Company, Limited ONE-STEP PROCEDURE FOR PURIFICATION OF ANTIBODIES USING ACTIVATED CARBON MATERIAL
WO2021099536A1 (en) 2019-11-22 2021-05-27 Morphosys Ag Method to increase antibody yield during ion exchange chromatography
WO2021139720A1 (zh) * 2020-01-08 2021-07-15 信达生物制药(苏州)有限公司 阿达木单抗纯化方法及其稳定组合物
KR102154952B1 (ko) * 2020-02-21 2020-09-10 프레스티지바이오로직스 주식회사 아달리무맙의 Non-Protein A 정제방법
WO2022245306A1 (en) * 2021-05-20 2022-11-24 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Protein purification by affinity chromatography
US12454567B2 (en) 2021-07-27 2025-10-28 Ariel Scientific Innovations Ltd. Large scale purification of antibodies
CN114133446A (zh) * 2021-12-31 2022-03-04 方坦思(上海)生物医药有限公司 单克隆抗体的纯化方法
CN115491328A (zh) * 2022-08-31 2022-12-20 深圳市卫光生物制品股份有限公司 一种大肠杆菌表达蛋白及其表达纯化方法
EP4335869A1 (en) 2022-09-07 2024-03-13 Bio T Biyoteknoloji Cozumleri Ve Uretim Anonim Resin and chromatography column that purifies antibodies with protease resistant small peptides
CN118725127B (zh) * 2024-07-11 2025-11-28 信立泰(苏州)药业有限公司 一种抗pcsk9单克隆抗体的分离纯化方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CN103641885A (zh) 1998-05-06 2014-03-19 基因技术股份有限公司 用离子交换层析纯化蛋白质
SI1308456T1 (sl) 1998-05-06 2008-02-29 Genentech Inc Ciscenje protiteles z ionsko izmenjevalno kromatografijo
EP1084136B1 (en) * 1998-06-01 2004-08-25 Genentech, Inc. Separation of antibody monomers from its multimers by use of ion-exchange chromatography
EP1614693A4 (en) 2003-03-31 2006-07-19 Kirin Brewery Purification of a human monoclonal antibody and human polyclonal antibody
JP5091476B2 (ja) 2003-06-27 2012-12-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用
SE0400501D0 (sv) 2004-02-27 2004-02-27 Amersham Biosciences Ab Antibody purification
CN104610422A (zh) 2005-03-11 2015-05-13 惠氏公司 弱分配层析的方法
JP5270337B2 (ja) 2005-06-17 2013-08-21 ヤンセン アルツハイマー イミュノセラピー 抗Ａβ抗体を精製する方法
US8263750B2 (en) 2006-03-16 2012-09-11 Amgen Inc. Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step
EP2738178A1 (en) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
CA2661645C (en) 2006-09-08 2016-11-08 Wyeth Arginine wash in protein purification using affinity chromatography
RU2010120674A (ru) * 2007-10-22 2011-11-27 Шеринг Корпорейшн (US) Полностью человеческие анти-vegf-антитела и способы их применения
WO2010030222A1 (en) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal with multimodal anion exchangers in the presence of protein-excluded zwitterions
US20100069617A1 (en) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions
EP2350127B1 (en) * 2008-10-20 2015-01-28 AbbVie Inc. Isolation and purification of antibodies using protein a affinity chromatography
SI3037104T1 (sl) 2009-10-20 2020-10-30 Abbvie Inc. Izolacija in prečiščevanje protiteles anti-IL-13 z uporabo afinitetne kromatografije beljakovine A
WO2011090719A2 (en) * 2009-12-29 2011-07-28 Dr. Reddy's Laboratories Ltd. Protein purification by ion exchange
KR101753569B1 (ko) 2010-01-22 2017-07-04 베링거 인겔하임 인터내셔날 게엠베하 Ｆｃ―함유 단백질을 정제하는 크로마토그래피 방법
CN102179237A (zh) * 2010-04-26 2011-09-14 无锡加莱克色谱科技有限公司 一种用于分离、提纯单克隆抗体和抗体球蛋白的亲和色谱填料及其制备方法
WO2012051147A1 (en) * 2010-10-11 2012-04-19 Abbott Laboratories Processes for purification of proteins
KR102027596B1 (ko) * 2010-12-06 2019-10-01 타폰 바이오시스템즈, 인코포레이티드 생물학적 산물을 위한 연속 처리 방법
WO2012125735A1 (en) 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
US20140128577A1 (en) * 2011-06-24 2014-05-08 Dr. Reddy's Laboratories Limited Purification of chimeric protein
US20140288278A1 (en) * 2011-10-31 2014-09-25 Joseph Nti-Gyabaah Chromatography process for resolving heterogeneous antibody aggregates
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
PL3395423T3 (pl) * 2013-03-14 2024-03-18 Amgen Inc. Usuwanie wypłukanych ligandów do oczyszczania na zasadzie powinowactwa
WO2014209508A1 (en) 2013-05-13 2014-12-31 Medimmune, Llc Separation of recombinant polyclonal antibody multimers with minimal separation of monomers
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法

Also Published As

Publication number Publication date
KR101683415B1 (ko) 2016-12-06
CA2911874A1 (en) 2014-12-31
TW201512217A (zh) 2015-04-01
MX2015016586A (es) 2016-03-16
AU2014300486B2 (en) 2016-06-30
ZA201508258B (en) 2017-03-29
TWI596107B (zh) 2017-08-21
CN105263947A (zh) 2016-01-20
MX350610B (es) 2017-09-11
SG11201509502XA (en) 2015-12-30
BR112015031196A2 (pt) 2017-07-25
JP6039828B2 (ja) 2016-12-07
HK1217344A1 (zh) 2017-01-06
US9708365B2 (en) 2017-07-18
EA201592192A1 (ru) 2016-07-29
US20160115195A1 (en) 2016-04-28
IN2013MU02145A (cg-RX-API-DMAC7.html) 2015-06-05
KR20160003311A (ko) 2016-01-08
WO2014207763A1 (en) 2014-12-31
JP2016525500A (ja) 2016-08-25
IL242649A (en) 2016-03-31
AU2014300486A1 (en) 2015-11-26
EP3013849A1 (en) 2016-05-04
EP3013849B1 (en) 2017-09-13
NZ714079A (en) 2017-05-26

Similar Documents

Publication Publication Date Title
AR096713A1 (es) Proceso de purificación para anticuerpos monoclonales
CL2020003409A1 (es) Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154)
AR096839A1 (es) Proceso mejorado para la producción de anticuerpos monoclonales
MX2015015482A (es) Proceso continuo de multiples etapas para purificar anticuerpos.
EA201300819A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
CR20180162A (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
EA201400875A1 (ru) Антитела к cd47 и способы их применения
MX364908B (es) Purificación de proteínas usando amortiguador bis-tris.
MX391041B (es) Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
CR20170032A (es) Moleculas biespecíficas de unión a antígeno activadoras de células t
PE20170704A1 (es) Agente terapeutico que induce citotoxicidad
AR094896A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
ECSP099572A (es) Anticuerpos monoclonales anti-cxcl13
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
JOP20200295A1 (ar) أجسام أحادية النوعية ومتعددة النوعية مضادة لـ tmeff2 المضاد واستخداماتها
BR112016028538A2 (pt) processo de produção de proteína glicosilada, processos de produção de proteína de fusão e anticorpo monoclonal e fragmento do mesmo, processo de produção de proteína de fusão tnfr-fc, proteína de fusão ou anticorpo monoclonal e fragmento do mesmo
BR112017001177A2 (pt) processo para a purificação de poliovírus a partir de culturas celulares
EA201692482A1 (ru) Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
MX2016013416A (es) Nuevo proceso de purificacion de gonadotropina.
ECSP20024551A (es) ANTICUERPO MONOCLONAL PARA IL-5Ra
BR112017019460A2 (pt) métodos e composições de piolisina
CL2016000874A1 (es) Anticuerpos anti-cd38 (divisional de sol. 1944-13).

Legal Events

Date Code Title Description
FB Suspension of granting procedure